# Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy

> **NCT00784888** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 344 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **OTHER:** Aromatase inhibitors

## Key facts

- **NCT ID:** NCT00784888
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784888, "Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00784888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*